Efficacy and safety evaluation of Azvudine in the treatment of COVID-19
based on four phase Ⅲ clinical trials.
Azvudine was included into the Guidelines for the Diagnosis and
Treatment of Coronavirus Disease 2019 (version ninth) issued by the
National Health Commission and National Administration of Traditional
Chinese Medicine announced on August 9, 2022. Numerous domestic public
hospitals introduced Azvudine to copy with the current omicron wave of
the COVID-19 pandemic by the end of 2022. In the study, we
comprehensively evaluated the efficacy and safety of Azvudine using the
clinical data from four phase Ⅲ clinical trials.